Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Regeneus Ltd. ( (AU:CMB) ) has issued an update.
Cambium Bio Limited announced that all resolutions at their General Meeting were passed, allowing the issuance of shares and options to key stakeholders, including Dr. Sebastian Tseng and Zheng Yang Biomedical Technology Co., Ltd. This approval supports the company’s A$3.0 million capital raising, which will fund the advancement of their lead product candidate, Elate Ocular®, towards Phase 3 clinical trials. With the FDA Fast Track designation and protocol approval, Cambium Bio is well-positioned to progress its clinical development program, enhancing shareholder value.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company that focuses on developing innovative biologics for ophthalmology and tissue repair applications.
YTD Price Performance: -2.50%
Average Trading Volume: 22,662
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$5.52M
See more insights into CMB stock on TipRanks’ Stock Analysis page.